74 results about "Heart failure cell" patented technology

An improved hemodynamic device may be collapsed and implanted percutaneously. The device includes at least one collapsible blade member and a rotary mover for rotating the blade member to provide hemodynamic circulation. In one embodiment of the invention, the blade member rotates within a basket after implantation. The basket may be formed of shape-memory wires.

Systems and methods for diagnosing one or more respiration distress manifestations by implantably recognizing their occurrence and evaluating information about the same to provide an indication of present or impending worsening heart failure are discussed. Using information produced by an implantable respiration sensor circuit and an implantable physiological sensor circuit, such as at least one of a physical activity sensor circuit or a posture sensor circuit, an implantable or external processor circuit may detect a respiration disturbance and an associated subsequent arousal from stable state occurrence and thereafter evaluate over time arousal from stable state occurrences to provide the indication of present or impending worsening heart failure. In one example, information about a fluid level within a subject is used in determining the indication of worsening heart failure. In various examples, a regimen is initiated or adjusted in response to the indication of present or impending worsening heart failure.

Systems and methods for detecting heart failure by monitoring the time-sequence of physiological changes of a subject using a state machine circuit configured to receive information about physiological characteristics of the subject is described. The current state transitions between a first and a second state in response to a first transition trigger. The current state transitions between the second and first states in response to at least one of the expiration of a first timer or ceasing of the first transition trigger. The current state transitions between the second and third states in response to a second transition trigger. The current state transitions between the third and second states in response to at least one of expiration of a second timer or ceasing of the second transition trigger.

The invention relates to a myocardial infarction and heart failure magnetic microparticle microfluidic biochip, which belongs to the technical field of POCT detection. The myocardial infraction and heart failure magnetic microparticle microfluidic biochip comprises a PCB board, wherein the PCB board is provided with a microflow passage, a biosensor is arranged in the microflow passage, the biosensor consists of a wafer platform and a point sample antibody covered on the wafer platform, the point sample antibody can form an immune complex with a magnetic bead coupling antibody and a marker protein, and the concentration of the marker protein can be judged by determining a magnetic resistance signal on the wafer platform. In the technical scheme, the magnetic bead has a larger specific surface area, and by combining more antibodies, the detection sensitivity is improved, and the specificity is higher than that of a fourth-generation chemical luminescent method. The invention also provides a detection method using the biochip. The heart markers such as myocardial infarction and heart failure can be simultaneously and quantitatively detected, the detection lower limit can be improved,and the leakage detection and false negative phenomenon can be effectively avoided.

A method is provided for reducing hypertension and/or heart failure in a mammal. Preferably, the method is used to treat or prevent tissue damage to a human heart. The method includes administering an effective amount of a Jak2 inhibitor, preferably a tyrphostin, such as AG490.

The invention relates to application of E1A-simulated gene cellular repressor (CREG) protein, in particular to application of CREG protein or active fragment thereof in preparation of drug used for preventing and/or treating acute myocardial infarction, heart failure after acute myocardial infarction and/or ventricular remodeling after the same. The invention further relates to application of recombinant vector or recombinant cell expressing the CREG protein or the active fragment thereof in preparation of the drug used for preventing and/or treating acute myocardial infarction, heart failure after acute myocardial infarction and/or ventricular remodeling after the same.

This invention provides methods of increasing blood flow to tissue in a subject in need thereof, methods of regenerating tissue in a subject, methods of treating diseased tissue in a subject, methods of forming new blood vessels in tissue and new tissue, such as myocardial tissue, in a subject in need thereof, methods of increasing angiogenesis in diseased tissue in a subject, and methods of preventing heart failure in a subject, which methods comprise: a) isolating autologous mononuclear cells from the subject; b) selecting from the isolated autologous mononuclear cells of step (a) lineage negative (Lin⁻) mononuclear cells; and c) transplanting locally into or adjacent to the tissue an effective amount of the Lin⁻ autologous mononuclear cells, resulting in formation of new blood vessels in the tissue and formation of new tissue. Additional methods provided for such uses further select from the isolated autologous mononuclear cells of step (a) lineage negative (Lin⁻) mononuclear cells a subset of Lin⁻ mononuclear side population (SP) cells and transplant locally into or adjacent to the tissue an effective amount of the Lin⁻ SP cells. In other aspects, methods using tissue other than mononuclear cells for these uses are provided, which comprise (a) obtaining a cell suspension from the tissue or a second tissue of the subject; (b) selecting from the cell suspension step (a) side population (SP) cells; and (c) transplanting locally into or adjacent to the tissue an effective amount of the SP cells, resulting in formation of new blood vessels in the tissue and formation of new tissue.

Endoglin has now been shown to be an important target of therapy to reduce disease symptoms associated with heart failure, particularly cardiac fibrosis. Soluble Endoglin is identified as an anatogonist to TGFβ1 activity, while membrane-bound Endoglin is identified as a necessary component to promote TGFβ1 activity in heart failure. The present invention therefore features methods and kits for treatment of subject having heart failure or a related disorder by administering a composition that decreases TGFβ1 signaling through either direct inhibition of membrane-bound Endoglin or promoting expression of soluble Endoglin.

The invention application presents a fast, efficient, reproductive alternative of a non-invasive method for diagnosing the severity of heart failure based on a specific biomarker. An additional object of the present invention is a collector device for the biomarker from exhaled breath that is portable, simple, low cost and does not need to run on electric power. This invention advantageously permits the replacement of invasive diagnosis methods, favoring the patient's comfort in addition to the agility and speed of medical attention at hospitals, and may become a standard method for all suspected cases of circulatory disease and heart failure and, more specifically, decompensated heart failure.

The invention discloses an immunochromatographic test strip for detecting cardiac infarction and heart failure and a preparation method thereof, and is intended to provide an immunochromatographic test strip that provides detection results accurately determinable and causes few cross reactions. The immunochromatographic test strip comprises a bottom board; a sample pad, a binding pad, a reaction film and an absorbing pad are linked to the bottom board; CRP (C-reactive protein) antibody and chicken IgY labeled by 300 nm immunofluorescence spheres are sprayed to the binding pad, and NT-proBNP antibody labeled by 200 nm immunofluorescence spheres is also sprayed thereto; the reaction film is parallelly provided with a C quality control line, a T1 detection line and a T2 detection line; the C quality control line is coated with goat anti-chicken IgY; the T1 detection line is coated with antigen CRP protein; the T2 detection line is coated with anti-NT-proBNP antibody.

The present invention relates to targeted RNAi for the treatment of heart failure by modulating defective cardiac Ca²⁺ homeostasis via decreasing expression or activity of phospholamban (PLB) using adeno-associated virus (AAV) transfection of cardiomyocytes. Methods for decreasing ventricular arrhythmias, as well as methods for overall improvement of survival from heart failure in subjects are also disclosed. Further, the present invention provides methods which can be used to diagnose susceptibility to treatment by RNAi, and includes pharmaceutical compositions, kits and vectors including an RNAi sequence.

Devices and methods for differentially diagnosing between worsening heart failure (HF) and other diseases or medical conditions are described. A medical system can receive patient information including one or more physiologic signals, and detect a respective physiologic feature from each of the one or more received physiologic signals. The medical system can include a differential diagnosis circuit that generates one or more signal metrics, receive two or more candidate conditions associated with the change in patient physical or physiological status, and determine a respective diagnostic score for each of the candidate conditions. The diagnostic score can indicate likelihood the change in the patient physical or physiologic status being caused by the corresponding candidate condition. A user interface can be provided to generate a presentation of the detected physiologic features and the diagnostic scores associated with the candidate conditions.

The invention discloses an analysis method for a vehicle-mounted battery pack pressure difference problem. The method includes firstly, analyzing the battery and finding out a failure module; secondly, testing the static voltage and the internal resistance of the failure module, wherein the failure module is divided into a failure module which is lower than the normal use voltage range but is higher than 0V, a failure module in a normal use voltage range and a failure module close to 0V according to the different static voltages; finally, finding out the failure cell from the failure module, dissembling the failure cell, and analyzing the failure reason and making the improvement. The method has the beneficial effects that starting from the differential pressure large fault module, the failure cell of the failure module can be analyzed through the capacity, direct-current internal resistance, disassembly, self-discharge analysis aspects, and the root cause of the cell failure is foundthrough disassembly of the cell, the cell production is guided to improve the cell quality, and the failure rate of the battery pack pressure difference is fundamentally reduced.

A health care system acquires data determines whether a patient is at risk of hypervolemia or hypovolemia. The method comprises (a) acquiring from a device memory a patient's absolute intrathoracic impedance data over a pre-specified time period, (b) determining a running average of the intrathoracic impedance data over the pre-specified time period, and (c) determining by the system whether the running average of the intrathoracic impedance data over the pre-specified time period exceeds one of a first and second range, the first range being a higher value boundary of intrathoracic electrical impedance and the second range being a lower value boundary of intrathoracic electrical impedance.

The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.

New methods and devices for treating heart failure and other cardiac disease conditions. Devices include a cardiac jacket adapted to fit generally around at least a portion of the heart. The jacket in some embodiments includes an electroactive polymer to squeeze the exterior of the heart to assist contraction of one or more pumping chambers, preferably the left ventricle. The jacket may also include stem cells on an inner surface of the jacket. The stem cells differentiate into cardiac tissue and help treatment of heart failure. Some embodiments also involve delivering an electric field or an electric current to electrically conductive material in the jacket to establish an electromagnetic field at the surface of the heart effective to promote growth and differentiation of stem cells into cardiac tissue.

The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.